Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: XR-Naltrexone Clear all
Completed Early Phase 1 Interventional Results available

Inpatient Single Dose Interventions for Alcohol Use Disorder

NCT04562779
View directory record Official record
Conditions
Alcohol Use Disorder, Severe
Interventions
Naltrexone 380 MG, Ketamine Hydrochloride, Enhanced linkage
Drug · Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 20, 2026, 3:28 AM EDT
Active, not recruiting Phase 2 Interventional

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

NCT04464980
View directory record Official record
Conditions
Opioid Use Disorder (OUD)
Interventions
SL-BUP, XR-BUP, XR-NTX, MM, MMR, MMD
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Little Rock, Arkansas • Tarzana, California • Bridgeport, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Not applicable Interventional Results available

Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone

NCT04762537
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Standard Induction Procedure (SP), Rapid Induction Procedure (RP)
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orlando, Florida • Rockville, Maryland • Cape Girardeau, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder

NCT03447743
View directory record Official record
Conditions
Opioid Dependence
Interventions
XR-NTX community location
Drug
Lead sponsor
Michele Staton
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 20, 2026, 3:28 AM EDT
Recruiting Phase 4 Interventional

Naltrexone in AUD Reward Drinkers

NCT05028062
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholism
Interventions
XR-NTX 380 mg, intramuscular injection, Medical Management, Placebo intramuscular injection
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 3 Interventional Results available

Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study

NCT01908062
View directory record Official record
Conditions
Opioid Use Disorder, Alcohol Use Disorder
Interventions
Extended Release Naltrexone, Treatment As usual
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 20, 2026, 3:28 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

NCT04408313
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
XR-B, XR-NTX
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone

NCT02294253
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 20, 2026, 3:28 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 4 Interventional

Pre-Release VIVITROL for Opioid Dependent Inmates

NCT01563718
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
naltrexone for extended release injectable suspension
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Oct 20, 2026, 3:28 AM EDT
Recruiting Not applicable Interventional

The Youth Opioid Recovery Support (YORS) Intervention

NCT04173416
View directory record Official record
Conditions
Opioid-use Disorder, Medication Adherence
Interventions
Youth Opioid Recovery Support (YORS)
Behavioral
Lead sponsor
Potomac Health Foundations
Other
Eligibility
18 Years to 28 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 20, 2026, 3:28 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol

NCT03113409
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine, Naltrexone, Vivitrol
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 2Phase 3 Interventional

EXHIT ENTRE Comparative Effectiveness Trial

NCT04345718
View directory record Official record
Conditions
Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Extended Release Buprenorphine, Treatment as Usual
Drug
Lead sponsor
Gavin Bart
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 4 Interventional Results available

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

NCT03799198
View directory record Official record
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 20, 2026, 3:28 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Depot NTX in Homeless Veterans

NCT01155869
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Depot naltrexone, Oral Naltrexone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

NCT03169816
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 3 Interventional Results available

Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail

NCT01180647
View directory record Official record
Conditions
Opiate Dependence
Interventions
Extended-Release Naltrexone, Motivational Enhancement Counseling
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

NCT01982643
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
naltrexone plus bupropion
Drug
Lead sponsor
Walter Ling
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry

NCT01999946
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Extended-Release Naltrexone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 4 Interventional Results available

Extended Release Naltrexone for Opioid-Dependent Youth

NCT01843023
View directory record Official record
Conditions
Drug Dependence
Interventions
Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
15 Years to 21 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 20, 2026, 3:28 AM EDT
Recruiting Phase 3 Interventional

Emergency Department-Initiated Medications for Alcohol Use Disorder

NCT05827159
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview, Gabapentin Pill
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

NCT03275350
View directory record Official record
Conditions
Opioid-use Disorder, Hiv
Interventions
Naltrexone Injectable Suspension, Treatment as usual
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Tarzana, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 20, 2026, 3:28 AM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

NCT05011266
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 3:28 AM EDT
Completed Phase 3 Interventional Results available

Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)

NCT02110264
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
XR-NTX, XR-NTX+PN, ETAU
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 100 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 20, 2026, 3:28 AM EDT